Savara (NASDAQ:SVRA) Earns Overweight Rating from Analysts at Wells Fargo & Company

Key Points

• Wells Fargo & Company has initiated coverage on Savara (NASDAQ:SVRA) with an "overweight" rating and a price target of $7.00, suggesting a potential upside of nearly 94%.
• Guggenheim and HC Wainwright have also issued positive ratings on Savara, with target prices of $11.00 and $8.00, respectively, while Weiss Ratings maintains a "sell" rating.
• Savara experienced a recent quarterly earnings miss, reporting a loss of ($0.14) per share, which was worse than the expected loss of ($0.12).

Analysts at Wells Fargo & Company assumed coverage on shares of Savara (NASDAQ:SVRA - Get Free Report) in a research report issued to clients and investors on Monday,Briefing.com Automated Import reports. The firm set an "overweight" rating and a $7.00 price target on the stock. Wells Fargo & Company's price target indicates a potential upside of 93.91% from the company's previous close.

SVRA has been the subject of a number of other research reports. Guggenheim raised their target price on Savara from $8.00 to $11.00 and gave the company a "buy" rating in a research note on Tuesday, September 9th. HC Wainwright raised their price objective on Savara from $5.00 to $8.00 and gave the company a "buy" rating in a research report on Wednesday, September 3rd. Weiss Ratings reaffirmed a "sell (d-)" rating on shares of Savara in a research report on Wednesday, October 8th. Lifesci Capital upgraded shares of Savara to a "strong-buy" rating in a report on Tuesday, October 14th. Finally, Oppenheimer raised their target price on shares of Savara from $6.00 to $8.00 and gave the company an "outperform" rating in a research note on Monday, September 8th. One analyst has rated the stock with a Strong Buy rating, five have issued a Buy rating, one has given a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, the company presently has a consensus rating of "Moderate Buy" and a consensus price target of $7.50.

Savara Price Performance

Shares of Savara stock opened at $3.61 on Monday. The company has a quick ratio of 11.08, a current ratio of 11.08 and a debt-to-equity ratio of 0.25. The company's fifty day simple moving average is $3.39 and its two-hundred day simple moving average is $2.89. The firm has a market cap of $623.95 million, a PE ratio of -7.22 and a beta of 0.46. Savara has a 12-month low of $1.89 and a 12-month high of $4.30.

Savara (NASDAQ:SVRA - Get Free Report) last released its quarterly earnings results on Wednesday, August 13th. The company reported ($0.14) earnings per share for the quarter, missing the consensus estimate of ($0.12) by ($0.02). As a group, equities analysts expect that Savara will post -0.45 EPS for the current year.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently modified their holdings of the business. Prudential Financial Inc. bought a new stake in Savara in the 2nd quarter worth about $30,000. BNP Paribas Financial Markets boosted its holdings in shares of Savara by 52.3% during the 2nd quarter. BNP Paribas Financial Markets now owns 13,473 shares of the company's stock valued at $31,000 after acquiring an additional 4,626 shares during the last quarter. May Hill Capital LLC bought a new stake in shares of Savara in the second quarter worth approximately $32,000. Brevan Howard Capital Management LP purchased a new position in shares of Savara during the second quarter valued at approximately $33,000. Finally, Quadrature Capital Ltd bought a new position in Savara during the second quarter valued at approximately $42,000. 87.93% of the stock is owned by institutional investors.

About Savara

Savara Inc, formerly Mast Therapeutics, Inc, is a clinical-stage pharmaceutical company. The Company is focused on the development and commercialization of novel therapies for the treatment of patients with rare respiratory diseases. Its pipeline includes AeroVanc, Molgradex and AIR001. AeroVanc is an inhaled formulation of vancomycin, which the Company is developing for the treatment of persistent methicillin-resistant Staphylococcus aureus, lung infection in cystic fibrosis patients.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.